Prevents bronchospasm. ANDA 78309, held by Mylan Speciality LP. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 78309 (Levalbuterol Hydrochloride), held by Mylan Speciality LP, was first approved by FDA on Mar 20, 2009, with 5 approved supplements and 0 published complete response letters.
Levalbuterol inhalation solution (concentrate) is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution (concentrate) is a beta 2 -adrenergic agonist indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levalbuterol HydrochlorideEQ 0.25% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Apr 12, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 25, 2017 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 25, 2017 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 10, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 19, 2013 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 20, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters